Literature DB >> 17245733

Fatal asthma in Finnish children and adolescents 1976-1998: validity of death certificates and a clinical description.

Kristiina Malmström1, Minna Kaila, Merja Kajosaari, Pirkko Syvänen, Kaisu Juntunen-Backman.   

Abstract

Several studies show that asthma mortality in children and adolescents increased until the mid-1990s, after which it has slightly decreased worldwide. The objective of this study was to describe the mortality rates of childhood asthma in Finland, and to analyze patient characteristics to identify predisposing factors for fatal asthma exacerbation among children and adolescents during 1976-1998 (2004). All death certificates where asthma or related respiratory tract disease was coded as the underlying cause of death were reviewed for those under 20 years of age. Health care records and autopsy reports were evaluated to validate the cause of death and to identify any predisposing factors. In all, there had been 28 asthma deaths. The validity of the death certificates proved to be good as only 7% were misclassified. Death occurred either in the very young children or adolescents: the median age in the group of <12 years (n = 15) was 3.3 years while the median age in the group of >12 years (n = 13) was 18.1 years. The fatal exacerbations occurred mostly during summer and early autumn. Clinical triggers, recorded for 14/22 patients with available patient records, included respiratory infection, (12) use of ibuprofen despite known allergy (1), and exercise after visiting a horse stable (1). The severity of the disease was discernible in 21 patients: severe in 15, moderate in 5, and mild in 1 patient. Inhaled corticosteroids were not used as maintenance or periodic therapy in 12/22 patients, of whom 4 had died during the 1990s. In conclusion, asthma mortality in Finnish children and adolescents was rare and its incidence remained stable. The validity of the death certificate diagnoses proved to be good. Poor asthma management and non or undertreatment with inhaled corticosteroids were risk factors for fatal asthma. 2007 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2007        PMID: 17245733     DOI: 10.1002/ppul.20552

Source DB:  PubMed          Journal:  Pediatr Pulmonol        ISSN: 1099-0496


  7 in total

1.  Management of severe asthma exacerbation in children.

Authors:  Xiao-Fang Wang; Jian-Guo Hong
Journal:  World J Pediatr       Date:  2011-10-20       Impact factor: 2.764

2.  Childhood asthma in low income countries: an invisible killer?

Authors:  Marianne Stubbe Østergaard; Rebecca Nantanda; James K Tumwine; Rune Aabenhus
Journal:  Prim Care Respir J       Date:  2012-06

3.  A single mouse monoclonal antibody, E58 modulates multiple IgE epitopes on group 1 cedar pollen allergens.

Authors:  Randall M Goldblum; Bo Ning; Barbara M Judy; Luis Marcelo F Holthauzen; Julius van Bavel; Atsushi Kamijo; Terumi Midoro-Horiuti
Journal:  Mol Immunol       Date:  2016-05-09       Impact factor: 4.407

4.  Design of peptides with high affinity binding to a monoclonal antibody as a basis for immunotherapy.

Authors:  Surendra S Negi; Randall M Goldblum; Werner Braun; Terumi Midoro-Horiuti
Journal:  Peptides       Date:  2021-08-16       Impact factor: 3.750

Review 5.  Incidence of fatal food anaphylaxis in people with food allergy: a systematic review and meta-analysis.

Authors:  T Umasunthar; J Leonardi-Bee; M Hodes; P J Turner; C Gore; P Habibi; J O Warner; R J Boyle
Journal:  Clin Exp Allergy       Date:  2013-12       Impact factor: 5.018

Review 6.  Working Towards an Appropriate Use of Ibuprofen in Children: An Evidence-Based Appraisal.

Authors:  Maurizio de Martino; Alberto Chiarugi; Attilio Boner; Giovanni Montini; Gianluigi L De' Angelis
Journal:  Drugs       Date:  2017-08       Impact factor: 9.546

7.  Immunohistology and remodeling in fatal pediatric and adolescent asthma.

Authors:  Kristiina Malmström; Jouko Lohi; Antti Sajantila; Frode L Jahnsen; Merja Kajosaari; Seppo Sarna; Mika J Mäkelä
Journal:  Respir Res       Date:  2017-05-16
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.